ASCOT analysis with atorvastatin shows limits of CRP as indicator of cardiovascular risk.

Lower on-treatment LDL-C but not hs-CRP was associated with a highly significant reduction in cardiovascular events over six months: An LDL-C less than the median of 2.1 mmol/l, compared with LDL-C at or higher than the median predicted a reduction in the composite endpoint at an adjusted OR of 0.41 (95% CI: 0.22–0.75, p = 0.004).

also in 132,142 other papers